Evidence map›Paper›PMID 42852008›Full record

ReviewFrontiers in cell and developmental biology2026

Geno-guided targeting of ferroptosis: a multi-layered network to overcome radioresistance in lung cancer.

Shifang Sang, Guangchao Lv, Shiyun Feng, Hui Zhao, Yulong Ren, Dianlong Jin, Kaizhong Wang

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shifang SangDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Guangchao LvDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Shiyun FengDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Hui ZhaoDepartment of Histology and Embryology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Yulong RenDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Dianlong JinDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Kaizhong WangDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the most prevalent and lethal malignancies worldwide, and radiotherapy serves as a standard therapeutic modality for the management of advanced or inoperable non-small cell lung cancer. However, radioresistance remains a major obstacle that compromises therapeutic efficacy and drives tumor recurrence. Ferroptosis-an iron-dependent, lipid peroxidation-governed form of regulated cell death-substantially contributes to radiation-mediated tumor cell elimination. This review establishes a multi-layered regulatory network through which ferroptosis mediates radioresistance in lung cancer, spanning genetic mutations, epigenetic and RNA-based regulation, protein post-translational modifications, and lipid metabolism reprogramming. Unlike existing reviews, this paper stratifies ferroptotic vulnerability and radiosensitivity according to common driver genotypes-including TP53, LKB1and KEAP1-and proposes a genotype-guided paradigm for precise radiosensitization. By integrating these molecular layers, review provides a supplementary theoretical framework for optimizing radiotherapy in lung cancer and highlights how targeting ferroptosis can overcome resistance in a mutation-specific manner. Furthermore, the crosstalk between ferroptosis and cuproptosis represents a promising combinatorial therapeutic avenue that warrants further preclinical and clinical investigation.

Indexed as

antioxidantscuproptosisferroptosislung cancerradiotherapy

Identifiers

PMID42852008
PMCPMC13647071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.